Mesenchymal stem cells in the treatment of pediatric diseases
Mesenchymal stem cells in the treatment of pediatric diseases
复制标题
间充质干细胞在儿科疾病治疗中的应用
DOI：
10.1007/s12519-013-0425-1
复制
发表时间：
2013-08
影响因子：
8.7
通讯作者：
Zheng GP, Ge MH, Shu Q, Rojas M, Xu J
中科院分区：
文献类型：
--
作者：
Zheng GP, Ge MH, Shu Q, Rojas M, Xu J
背景近年来，人们对间充质干细胞的极大兴趣提高了患者和医生的期望。与胚胎干细胞不同，它们的获取和使用都没有争议。此外，它们的免疫调节能力加上低免疫原性，开辟了它们的同种异体用途，从而扩大了它们的应用的可能性。2012年5月，加拿大卫生监管机构批准了第一种基于间充质干细胞的药物Prochymal，用于治疗对类固醇治疗无效的儿童的急性移植物抗宿主病。本文的目的是回顾间充质干细胞用于儿科疾病的最新进展。数据来源使用MeSH术语“间充质干细胞”、“临床试验”和“儿童”在PubMed上进行了1966年至2013年的文献综述。额外的文章被确定的手搜索的参考文献列表在初始search.ResultsThe以下类别进行了说明：一般性质、作用机制、移植物抗宿主疾病、心血管疾病、肝脏疾病、炎症性肠病、骨关节疾病、自身免疫疾病、1型糖尿病和肺部疾病。低免疫原性和治疗潜力已经成为治疗多种疾病的最有吸引力的选择之一。在不久的将来，间充质干细胞在儿科疾病中的临床试验和应用将会越来越多。
BackgroundIn recent years, the incredible interests in mesenchymal stem cells have boosted the expectations of both patients and physicians. Unlike embryonic stem cells, neither their procurement nor their use is deemed controversial. Moreover, their immunomodulatory capacity coupled with low immunogenicity has opened up their allogenic use, consequently broadening the possibilities for their application. In May 2012, Canadian health regulators approved Prochymal, the first mesenchymal stem cells-based drug, for acute graft-versus-host diseases in children who have failed to respond to steroid treatment. The aim of this article is to review the recent advances in mesenchymal stem cells for pediatric diseases.Data sourcesA literature review was performed on PubMed from 1966 to 2013 using the MeSH terms “mesenchymal stem cells”, “clinical trials” and “children”. Additional articles were identified by a hand search of the references list in the initial search.ResultsThe following categories are described: general properties, mechanisms of action, graft-versus-host diseases, cardiovascular diseases, liver diseases, inflammatory bowel diseases, osteoarticular diseases, autoimmune diseases, type 1 diabetes, and lung diseases.ConclusionsMesenchymal stem cells, owing to their availability, immunomodulatory properties, low immunogenicity, and therapeutic potential, have become one of the most attractive options for the treatment of a wide range of diseases. It is expected to see more and more clinical trials and applications of mesenchymal stem cells for pediatric diseases in the near future.
登录
查看更多内容
影响因子：
20.3
作者：
Sato, Kazuya;Ozaki, Katsutoshi;Ozawa, Keiya
通讯作者：
Ozawa, Keiya
影响因子：
3.3
作者：
Diekman BO;Wu CL;Louer CR;Furman BD;Huebner JL;Kraus VB;Olson SA;Guilak F
通讯作者：
Guilak F
影响因子：
20.1
作者：
Williams AR;Trachtenberg B;Velazquez DL;McNiece I;Altman P;Rouy D;Mendizabal AM;Pattany PM;Lopera GA;Fishman J;Zambrano JP;Heldman AW;Hare JM
通讯作者：
Hare JM
影响因子：
7.5
作者：
Ben Azouna N;Jenhani F;Regaya Z;Berraeis L;Ben Othman T;Ducrocq E;Domenech J
通讯作者：
Domenech J
影响因子：
2.1
作者：
M. Mohamadnejad;K. Alimoghaddam;M. Mohyeddin-Bonab;M. Bagheri;M. Bashtar;H. Ghanaati;H. Baharvand;A. Ghavamzadeh;R. Malekzadeh
通讯作者：
M. Mohamadnejad;K. Alimoghaddam;M. Mohyeddin-Bonab;M. Bagheri;M. Bashtar;H. Ghanaati;H. Baharvand;A. Ghavamzadeh;R. Malekzadeh